Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 643-647

  Schmidt, Stefan ^a   Gastl, Guenther ^a   Wolf, Dominik ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CD34+ stem cells; CML; Gene expression profiles; Prognostication

Indexed keywords

DNA; IMATINIB; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

APOPTOSIS; BONE MARROW; CELL ADHESION; CELL CYCLE; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CONFERENCE PAPER; CYTOGENETICS; DNA MICROARRAY; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; LEUKAPHERESIS; LEUKEMIA CELL; LEUKOCYTE; METABOLISM; MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STATISTICAL ANALYSIS; STEM CELL; TRANSCRIPTION REGULATION; VALIDATION PROCESS;

GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHARMACOGENETICS; PROGNOSIS;

EID: 42049088802     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801896194     Document Type: Conference Paper

References (21)

1. Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J. and Larson, R. A. (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood, 108, pp. 1478-1484.
2. Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M. and Kluin-Nelemans, J. C. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst, 90, pp. 850-858.
3. Sokal, J. E., Cox, E. B., Baccarani, M., Tura, S., Gomez, G. A. and Robertson, J. E. (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 63, pp. 789-799.
4. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B. and Appelbaum, F. (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, pp. 1809-1820.
5. Bullinger, L., Dohner, K., Bair, E., Frohling, S., Schlenk, R. F. and Tibshirani, R. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med, 350, pp. 1605-1616.
6. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. and Chan, W. C. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
7. Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P. and Sawyers, C. L. (2005) Dynamics of chronic myeloid leukaemia. Nature, 435, pp. 1267-1270.
8. Crossman, L. C., Mori, M., Hsieh, Y. C., Lange, T., Paschka, P. and Harrington, C. A. (2005) In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica, 90, pp. 459-464.
9. Yong, A. S., Szydlo, R. M., Goldman, J. M., Apperley, J. F. and Melo, J. V. (2006) Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood, 107, pp. 205-212.
10. Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J. and Druker, B. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA, 103, pp. 2794-2799.
11. Frank, O., Brors, B., Fabarius, A., Li, L., Haak, M. and Merk, S. (2006) Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia, 20, pp. 1400-1407.
12. McLean, L. A., Gathmann, I., Capdeville, R., Polymeropoulos, M. H. and Dressman, M. (2004) Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res, 10, pp. 155-165.
13. Villuendas, R., Steegmann, J. L., Pollan, M., Tracey, L., Granda, A. and Fernandez-Ruiz, E. (2006) Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia, 20, pp. 1047-1054.
14. Tipping, A. J., Deininger, M. W., Goldman, J. M. and Melo, J. V. (2003) Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol, 31, pp. 1073-1080.
15. Hagberg, A., Olsson-Stromberg, U., Wickenberg-Bolin, U., Goransson, H., Isaksson, A. and Bengtsson, M. (2007) Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients. Leuk Res, 31, pp. 931-938.
16. Nowicki, M. O., Pawlowski, P., Fischer, T., Hess, G., Pawlowski, T. and Skorski, T. (2003) Chronic myelogenous leukemia molecular signature. Oncogene, 22, pp. 3952-3963.
17. Ohmine, K., Ota, J., Ueda, M., Ueno, S., Yoshida, K. and Yamashita, Y. (2001) Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene, 20, pp. 8249-8257.
18. Zheng, C., Li, L., Haak, M., Brors, B., Frank, O. and Giehl, M. (2006) Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia, 20, pp. 1028-1034.
19. Kronenwett, R., Butterweck, U., Steidl, U., Kliszewski, S., Neumann, F. and Bork, S. (2005) Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene, 24, pp. 5313-5324.
20. Diaz-Blanco, E., Bruns, I., Neumann, F., Fischer, J. C., Graef, T. and Rosskopf, M. (2007) Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia, 21, pp. 494-504.
21. Cohen, N., Rozenfeld-Granot, G., Hardan, I., Brok-Simoni, F., Amariglio, N. and Rechavi, G. (2001) Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: Expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genetics Cytogenetics, 128, pp. 114-119.